By Anton Ladnyi, CFA · ex-Goldman Sachs · ex-J.P. MorganPublished Updated
CCJ — uranium's blue-chip platform at 37x EV/EBITDA: Q1 2026 adj EBITDA +44% YoY to $509M, realized price $66.21/lb vs. spot $84/lb and Citi's $100–$125 target; Westinghouse 49% stake transforms CCJ into a nuclear infrastructure platform; utilities structurally under-contracted through 2030; premium multiple reflects cycle leadership but limits near-term entry
CCJ Price Target & Rating
CCJ's quantitative grade is Reduce, with moderate downside risk (CVaR -16.4%), and quality metrics (net margin 18%, ROE 10%). Cameco Corporation (CCJ) trades at $112.70 with a valuation grade of Reduce: a trailing P/E of 105.3x at a 778% premium to sector median, net margins of 18.4%, a DCF-implied intrinsic range of $61–$124 suggesting a -18% margin of safety, beta 1.03 (moderate risk profile).
DCF Valuation Range
Key Takeaways
Valuation: Reduce grade — P/E 105.3x — DCF range $61–$124 implies -18% margin of safety
Risk: CVaR -16.4% (95th percentile, 1-month) indicates moderate tail exposure; beta of 1.03 amplifies broad market moves in both directions
Strengths: 18% net margin, 10% ROE dominate the factor profile
Catalyst: Uranium spot crossing $100/lb (Citi 2026 base case) triggers contract price resets; Q2 2026 earnings (August) for uranium production and realized price update; U.S. uranium reserve procurement contracts awarded from $3.3B appropriation; Westinghouse AP1000 construction announcements exceeding 20 reactors
Bear catalyst: Uranium spot falls below $60/lb on Kazakhstan supply surprise or demand reassessment; JV Inkai production disrupted by geopolitical event reducing Cameco output by more than 15%; major utility customer delays or cancels long-term uranium contract; Westinghouse operational issues cause guidance cut at CCJ group level
CCJ — Quantitative SnapshotMay 2026
RatingReduce
Price$112.70
Why ReduceModestly above estimated intrinsic value — risk/reward skewed to the downside at current price; watch for a pullback to the Hold boundary
Main riskP/E of 105.3x creates asymmetric downside on any earnings disappointment
Tail riskCVaR -16.4% over one month at the 95th percentile
DCF range$61–$124 intrinsic range; margin of safety -18%
Best useCore large-cap Energy holding — not a source of diversified sector exposure
Next watchEarnings delivery consistency and margin trajectory
Quantitative Factor Profile
Value
2.0 / 5
Quality
3.0 / 5
Momentum
3.0 / 5
Volatility
3.0 / 5
Size
3.0 / 5
Key Metrics
CCJ Key Metrics — Cameco Corporation 2026
Metric
Value
Current Price
$112.70
P/E Ratio (TTM)
105.3x
Forward P/E
58.7x
PEG Ratio
0.67x
P/S Ratio
13.9
EV/EBITDA
54.8
Beta
1.03
Net Margin
18.4%
ROE
9.6%
Debt/Equity
14.3%
Dividend Yield
0.15%
CVaR (95%, 1M)
-16.4%
Market Cap
$49.1B
Analyst View
Anton Ladnyi, CFA · A.L. Capital AdvisoryUpdated 2026-05-31
Rating Rationale
CCJ — uranium's blue-chip platform at 37x EV/EBITDA: Q1 2026 adj EBITDA +44% YoY to $509M, realized price $66.21/lb vs. spot $84/lb and Citi's $100–$125 target; Westinghouse 49% stake transforms CCJ into a nuclear infrastructure platform; utilities structurally under-contracted through 2030; premium multiple reflects cycle leadership but limits near-term entry
Investment Thesis
↑ Bull Case
Q1 2026 adj EBITDA +44% YoY to $509M with uranium realized price at $66.21/lb — a $17–18 discount to spot ($84/lb) and $34/lb below long-term contract prices ($100/lb); as below-market legacy contracts roll off through 2026–2028 and reset at market, Cameco adds $500–700M in incremental annual EBITDA on flat volumes, entirely from price realization
Uranium utilities are dramatically under-contracted: global utility coverage drops below 50% for deliveries from 2027 onward, forcing a multi-year re-contracting wave at structurally higher prices; Cameco is the only investment-grade Western primary uranium producer at scale and gets first call on new long-term utility contracts
Westinghouse 49% stake acquired 2023 transforms CCJ from commodity miner to nuclear infrastructure platform: Westinghouse services ~50% of the global reactor fleet and is sole AP1000 supplier for 20 new U.S. reactors entering construction; this adds a high-margin recurring services revenue stream insulated from uranium spot price volatility
Citi projects uranium spot to $100–$125/lb in 2026 (from $84 currently); Scotiabank raised PT to $175; at $100/lb uranium, Cameco's market-based contracts reset and EBITDA accelerates to $2B+ annualized — 2026 consensus EPS of $1.20 does not model uranium above $80/lb
AI data center power demand creates a new structural uranium demand vector: hyperscalers actively contracting nuclear power (Microsoft, Google, Amazon, Meta all signed nuclear PPAs) drives urgency for new reactor construction; Cameco's GLE stake (laser enrichment) positions it as a one-stop shop for enriched uranium supply to new reactors
↓ Bear Case
At 37x EV/EBITDA and 125x trailing P/E, CCJ is priced for near-perfection; any uranium spot price pullback from $84 toward $60–65 on demand reassessment or Kazakhstan supply surprise re-rates the stock sharply — 29.3% YTD gain already embeds significant optimism
JV Inkai (Kazakhstan, 21.7% of 2025 production) carries geopolitical risk; any disruption to Kazakh uranium exports — which supply ~45% of global spot — creates short-term Cameco production gaps that Canadian mines alone cannot rapidly replace
Nuclear new-build timelines routinely slip 2–5 years: the 20 AP1000 U.S. reactors will not consume uranium for 5–8 years; interim demand depends on life extensions of existing fleet, a slower-moving catalyst that does not justify the implied $100+/lb long-term contract price urgency on a 12-month horizon
Westinghouse integration risk: Cameco acquired 49% of a large, complex multinational at a peak valuation multiple; any execution issues, cost overruns, or project delays at Westinghouse reduce earnings quality and make the premium CCJ EV/EBITDA multiple harder to justify vs. pure-play uranium comps
What Changes the Rating
↑Catalyst:Uranium spot reaches $100/lb and Cameco raises 2026 realized price guidance above $75/lb; additional long-term utility contracts announced at $95+/lb; Westinghouse AP1000 backlog confirmed above $10B; JV Inkai meets full 2026 production guidance without disruption
↓Stop / exit:Uranium spot falls below $60/lb on Kazakhstan supply surprise or demand reassessment; JV Inkai production disrupted by geopolitical event reducing Cameco output by more than 15%; major utility customer delays or cancels long-term uranium contract; Westinghouse operational issues cause guidance cut at CCJ group level
Anton’s personal note
The rating on CCJ is driven by a factor profile that is genuinely mixed — there is no clean narrative here, which is itself a signal worth taking seriously. The variable I track most closely is gross margin trajectory. That multiple can only be sustained if operating leverage is real — specifically whether the margin profile at scale supports what the market is already pricing in, or whether that future still needs to be earned. The scenario that changes my read is a genuine valuation reset — not a small pullback, but a re-rating that reflects the actual risk profile. Until that happens, the risk/reward is not there.
— Anton Ladnyi, CFA
Earnings History
CCJ Earnings History — EPS Surprise Rate 2026
Quarter
EPS Est.
EPS Actual
Surprise
Q1 2026
$0.34
$0.47
+38.1% ✓
Q4 2025
$0.44
$0.50
+12.9% ✓
Q3 2025
$0.27
$0.07
-74.5% ✗
Q2 2025
$0.52
$0.71
+37.6% ✓
Quarterly EPS — Estimate vs Actual
Earnings Projections
CCJ Forward EPS Consensus Estimates 2026
Quarter
EPS Est.
YoY EPS
Analysts
Q2 2026
$0.36
-49.3%
9
Q3 2026
$0.32
+360.3%
9
Q4 2026
~$0.43
-14.0%
15
Q1 2027
~$0.66
+40.4%
19
~ Estimated from annual consensus — not a direct analyst survey
CCJ — P/E 105.3x · Beta 1.03 • Quantitative grade: Reduce • CVaR from one-year daily history · historical simulation
DCF Scenario Analysis
Hover each scenario for detail · current price $112.70
▼
Bear Case
$52
-53.9%
Fwd P/E: 29.3x
5% revenue CAGR · 20x exit multiple
◆
Base Case
$145
+28.7%
Fwd P/E: 81.8x
15% revenue CAGR · 30x exit multiple
▲
Bull Case
$200
+77.5%
Fwd P/E: 112.9x
25% revenue CAGR · 38x exit multiple
Pairwise Correlation Matrix
1 of 10 peer pairs correlated above 0.60 — diversification benefit within this cluster is structurally limited.
Extended Analysis — Buy, Hold or Sell? Risk Factors. Portfolio Fit.
Is CCJ a buy, hold, or sell?
CCJ carries a valuation grade of Reduce. The trailing P/E of 105.3 sits 778% above the Energy sector median of 12.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $61–$124 — implying a -18% margin of safety at the current price of $112.70. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 9% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 38.1% earnings surprise. Analyst estimate revisions are trending upward.
What are CCJ's key risk factors?
With a beta of 1.03, CCJ exhibits a market-neutral risk profile relative to the broad market. The 95th-percentile CVaR of -16.4% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 1.6% of total portfolio loss in the worst 5% of months. Net margins of 18.4% are significantly above the Energy sector average of 10%, reflecting durable pricing power. The balance sheet is conservatively leveraged at 14% debt-to-equity.
The options market shows a put/call ratio of 6.05, reflecting a notably bearish skew in derivative positioning. Implied and realized volatility are roughly aligned at 57.8% and 53.9% respectively.
How does CCJ fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — CCJ carries a beta of 1.03, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, CCJ shows the strongest co-movement with VRT (0.42), GEV (0.41), CEG (0.35). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The CCJ analysis here is a single node in that larger structure.
Cameco Corporation (CCJ) carries a Reduce quantitative rating from A.L. Capital Advisory, derived from Discounted Cash Flow intrinsic value analysis, five-factor model scoring (Value, Quality, Momentum, Volatility, Size), and CVaR tail risk measurement. At $112.70, the DCF midpoint margin of safety is -18% (intrinsic value range: $61 bear – $124 bull). Composite factor score: 2.8/5. Strongest factor: Quality (3.0/5). Weakest factor: Value (2.0/5). Trailing P/E: 105.3x. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Portfolio Construction Framework →
What is the average analyst target price for CCJ?
Wall Street consensus target for CCJ: $130.07 (+15.4% upside from the current price of $112.70). The analyst target range spans $81.75 (most bearish) to $172.71 (most bullish). Consensus recommendation: Buy. Note that analyst price targets typically reflect a 12-month forward horizon and are derived from a blend of DCF, comparable-company, and sum-of-the-parts analysis. A.L. Capital Advisory’s quantitative Reduce rating is produced independently — from DCF intrinsic value, five-factor model scores, and CVaR tail risk — and does not mechanically track Street consensus. When the two diverge, the divergence itself is informative: it can reflect differences in time horizon, valuation methodology, or the degree to which the current price already discounts the consensus case. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Monte Carlo Simulation Framework →
How does CCJ score on Value, Quality, Momentum, Volatility, and Size?
CCJ five-factor scores (A.L. Capital Advisory, 1–5 scale): Value 2.0/5 (below average) — measures current price versus DCF intrinsic range and trailing earnings multiples; Quality 3.0/5 (neutral) — captures profitability metrics including return on equity, net margin (ROE: 9.6%) and net margin (18.4%); Momentum 3.0/5 (neutral) — reflects recent price trajectory and earnings surprise consistency; Volatility 3.0/5 (neutral) — inverse measure derived from beta, where lower historical volatility earns a higher score; Size 3.0/5 (neutral) — market capitalisation rank (mega-cap $1T+ scores 5/5). Composite: 2.8/5. Factor scores above 4.0 signal a tailwind in that dimension; below 2.0 signals a material headwind. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Black-Litterman Model →
What is CCJ's tail risk and CVaR?
The 95th-percentile Conditional Value at Risk (CVaR) for CCJ on a one-month horizon is -16.4%. CVaR represents the expected average loss in the worst 5% of monthly outcomes — a more conservative tail risk measure than standard VaR, which only marks the loss threshold. Beta of 1.03 indicates broadly market-level volatility. For reference, a diversified S&P 500 ETF carries a one-month CVaR of roughly -8% to -12% in normal market conditions; individual equity CVaR is higher due to idiosyncratic risk. At the portfolio level, what matters is the marginal CVaR contribution of each holding — not its standalone figure. The A.L. Capital Advisory Portfolio Health Check quantifies each position's marginal tail-risk contribution across your entire holdings. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: CVaR & Tail-Risk Methodology →
What is CCJ's intrinsic value and DCF price target?
A.L. Capital Advisory's DCF model produces an intrinsic value range of $61 (bear case) to $124 (bull case) for Cameco Corporation (CCJ). At $112.70, the midpoint margin of safety is -18% (positive = discount to intrinsic mid; negative = premium). The bear-to-bull spread reflects genuine sensitivity to the two dominant DCF inputs: the terminal growth rate and WACC. Terminal value typically accounts for 60-80% of total intrinsic value in most equity DCF models, which is why a range is more analytically sound than a point estimate. The central analytical question is not what the DCF outputs as a single number but which growth trajectory the current market price already discounts. All DCF analysis follows CFA Institute standards and is conducted by Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →
What would trigger a rating upgrade or downgrade for CCJ?
Upgrade trigger: Upgrade to Strong Buy on evidence of accelerating earnings surprise magnitude combined with improvement in the Value factor score — specifically if the current 105.3x P/E is supported by an upward revision to DCF terminal growth assumptions. Downgrade trigger: Continued earnings misses or deteriorating balance sheet quality reducing the Quality factor score below 2.0/5. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Investment Policy Statement Framework →
Does CCJ consistently beat earnings estimates?
CCJ has beaten consensus EPS estimates in 9% of tracked quarterly periods — indicating inconsistent delivery. The most recent reported quarter beat consensus by 38.1%. Below-average earnings consistency is a primary headwind to the rating and a key watch item in the quantitative model. Earnings surprise magnitude and direction are incorporated into the Momentum and Quality dimensions of the five-factor scoring model. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →
How does CCJ contribute to portfolio risk and diversification?
CCJ carries a beta of 1.03 (moderate-volatility relative to the broad equity market). A beta above 1.0 means the position amplifies market moves in both directions at a typical portfolio weight. Strongest peer co-movement: VRT (0.42), GEV (0.41), CEG (0.35). Holding CCJ alongside these names in the same portfolio increases concentration risk. True portfolio risk is a function of the full covariance structure — a single stock's beta does not reveal its marginal contribution to portfolio tail loss. The A.L. Capital Advisory Portfolio Health Check quantifies concentration risk (Herfindahl-Hirschman Index), pairwise correlations, and marginal CVaR contribution across all your holdings. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Ledoit-Wolf Covariance Framework →
What quantitative methodology does A.L. Capital Advisory use to analyse CCJ?
A.L. Capital Advisory analyses Cameco Corporation (CCJ) using a four-component quantitative framework grounded in CFA Institute standards. (1) DCF Valuation: projects free cash flows under bear and bull assumptions, discounts at WACC to produce an intrinsic value range with margin-of-safety calculation. (2) Five-Factor Scoring: each equity is scored 1–5 on Value, Quality, Momentum, Volatility, and Size. (3) CVaR Tail Risk: 95th-percentile Conditional Value at Risk from historical simulation of daily returns on a one-month horizon. (4) Earnings Surprise Analysis: quarterly beat rate and magnitude are incorporated into the Momentum and Quality factor scores. The current Reduce rating for CCJ is the output of applying this complete framework to current data. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework → · CVaR & Tail-Risk Methodology →
Stress-Test This View Live
Run CCJ in Asset Lens
Live DCF valuation, Monte Carlo simulation, options flow intelligence, and full factor decomposition — updated in real time. Free, no account required.
This analysis is produced using a systematic quantitative framework applied to market data and does not constitute investment advice. Prose commentary is AI-assisted and generated from structured quantitative inputs. All data and metrics are as of 2026-05-31 and are point-in-time estimates subject to revision without notice. CVaR figures are based on historical simulation and do not guarantee future outcomes. DCF ranges and upgrade/downgrade triggers are forward-looking statements based on current assumptions and may not materialise. Past performance does not guarantee future results. This analysis does not account for individual circumstances, tax position, or investment objectives — consult a qualified financial advisor before making investment decisions. This content is intended for informational purposes only and does not constitute regulated investment advice under MiFID II or FCA guidelines. This content is not intended for US persons or residents of jurisdictions where its distribution would be contrary to local law or regulation. This service is not directed at residents of Finland, Sweden, Norway, Denmark, Iceland, or Poland. The author may hold long or short positions in securities mentioned in this analysis. Nothing on this page represents a solicitation to buy or sell any security. A.L. Capital Advisory is an independent private advisory practice and is not affiliated with Cameco Corporation.
CFA Portfolio Advisory — CCJ
Discuss this analysis, position sizing, or your full portfolio mandate with Anton Ladnyi, CFA.
